Jay Duker's guest appearances

Jay Duker

OIS Podcast

The Retina Channel Podcast

BroadEye: An Ophthalmology Podcast

David Pyott

Jay Cormier

John Kennedy

Brent Saunders

Daniel Chao

David Muller

Andrew Chang

John Nolan

David Tanzer

Ken Mills

Bill Link

Patrick Mooney

Ashley Alexander

Ian MacDonald

Anthony Ferraro

OwlTail

Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD. 

Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD.

E67-DAVIO Trial- extended release EYP-1901 for wet AMD- Dr. Jay Duker

Dr. Duker is an accomplished ophthalmologist, that is now the Chief Operating Officer of EyePoint Pharma, a biotech company that develops sustained-release medications to treat serious ocular disorders. We talked about his career path and what motivated him to move from a clinical to an executive position. For the 21 years before he took the COO position at EyePoint, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center, Tufts University School of Medicine in Boston, Massachusetts. Dr. Duker received his medical degree from Jefferson Medical College. He completed a residency and fellowship in vitreoretinal diseases and ocular oncology at the Wills Eye Hospital.

Dr. Duker is an accomplished ophthalmologist, that is now the Chief Operating Officer of EyePoint Pharma, a biotech company that develops sustained-release medications to treat serious ocular disorders. We talked about his career path and what motivated him to move from a clinical to an executive position. For the 21 years before he took the COO position at EyePoint, Dr. Duker was the Director of the New England Eye Center (NEEC) and Professor and Chair of the Department of Ophthalmology at Tufts Medical Center, Tufts University School of Medicine in Boston, Massachusetts. Dr. Duker received his medical degree from Jefferson Medical College. He completed a residency and fellowship in vitreoretinal diseases and ocular oncology at the Wills Eye Hospital.

From the operating room to the C-suite in pharma - Dr. Jay Duker

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

We dip into the gene therapy pool one more time, talking with Jay Duker, MD about Luxturna’s impact on ophthalmology. We also discuss how the acquisitions of Spark and Nightstar are benefiting earlier-stage gene therapy start-ups, including his own Hemera Biosciences.

What Impact Will Gene Therapy Deals Have on Patients? Start-Ups? Jay Duker, MD, Can Speak for Both.